Skip to NavigationSkip to content


Ablynx's vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial, presenting implications for Sanofi who will acquire the drug following its agreement to buy the firm for $4.8 billion.

AbbVie secures further strong results for potential blockbuster

AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids and endometriosis.

Hopes on this front have been boosted by further Phase 3 results that have indicated that AbbVie stands in a good position to go in front of the FDA for an indication in uterine fibroids.

Top Ten most popular articles on this week

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter here in the UK. So there's the hope that Spring is just around the corner as we pass another Friday and another top ten rundown of the week's most popular articles.

Top Ten most popular articles on this week

It's the last Friday of February, and it's time for another run-down of the most popular stories of the week.

One of the biggest stories this week was the ongoing news that 10 Greek politicians are to be investigated on their alleged bribery and collusion with major pharma firm Novartis. It's a shocking, if unsurprising episode that will continue to hold interest as it develops.

AbbVie turns to tau for Alzheimer’s in $1.1bn deal

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion with Voyager Therapeutics.

The news is a positive note amongst a fair amount of doom-and-gloom in the hopes of finding a treatment for Alzheimer’s in the near future, perhaps exemplified best by Pfizer’s decision to exit the neuroscience area at the beginning of the year.

Death in trial blackens AbbVie’s positive rheumatoid arthritis data

AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the drug will linger over the deaths it has seen in trials.

In the most recent trial, a patient died from a ruptured aneurysm and another patient suffered a non-fatal pulmonary embolism. The death in this recent trial follows on from two deaths in a previous Phase 3 trial where one patient died due to heart failure and blood clots in the lungs.

AbbVie posts strong psoriasis data but can it stand out from crowd?

AbbVie revealed that its IL-23 inhibitor, risankizumab, had successfully met all of its endpoints in a Phase 3 trials into the treatment of moderate to severe plaque psoriasis. The results are promising but the question remains whether it can play catch-up in an already crowded market?

Only a few weeks ago, Johnson & Johnson had scored European Commission approval for Tremfya, after already having achieved a nod from the FDA in July for the treatment of moderate to severe plaque psoriasis.

AbbVie’s psoriasis drug smashes all endpoints

AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat at the top of the heap for years. It may be getting excited again about the potential of its new treatment, risankizumab, to perform strongly in the area after it met all of its primary and secondary endpoints.

However, risankizumab will enter a very different market – with a huge amount of competition in the area. Should it be approved, it would join Novartis Cosentyx, Novartis’ Ilaris, Eli Lilly’s Taltz, Valeant’s Siliq and J&J’s Tremfya.

AbbVie hit with $140m fine over fraudulent marketing of Androgel

AbbVie has been stung with a $140 million damages award to a man that suffered a heart attack after using its product Androgel, a testosterone replacement therapy.

The warning signs had been there for the company, with a similar finding in a case tried in Illinois in July handed a $150 million verdict against it in a similar case.

AbbVie adds biologic production capability to Singapore facility

AbbVie has expanded the operational capability of its facility located at the Tuas Biomedical Park in Singapore with the addition of a biologics manufacturing facility. The move means the plant will now add the production of biological drugs to its repertoire in addition to small molecule active pharmaceutical ingredients (APIs).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches